Cercar
01/01/2025
Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse
Martinez-Recio, S, Molina-Pérez, MA, Muñoz-Couselo, E, Sevillano-Tripero, AR, Aya, F, Arance, A, Orrillo, M, Martin-Liberal, J, Fernandez-Morales, L, Lesta, R, Quindós-Varela, M, Nieva, M, Vidal, J, Martinez-Perez, D, Barba, A, Majem, M. Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse. Cancers. 2025; 17(1)DOI:10.3390/cancers17010143. PMID:39796770. IF:4.400(Q2/3D).
01/01/2025
Quality of Life and Patient-Reported Outcomes in Patients With Osteosarcoma: A Systematic Review
Sebio, A, Berger, C, Tabone, MD, Fernandez, N, Tardy, F, Grootenhuis, M, Palmerini, E, Gaspar, N, van de Sande, M, Haveman, LM. Quality of Life and Patient-Reported Outcomes in Patients With Osteosarcoma: A Systematic Review. EUROPEAN JOURNAL OF CANCER CARE. 2025; 2025(1)DOI:10.1155/ecc/5802523. PMID:. IF:1.900(Q2/4D).
17/12/2024
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study
Piedra, A, Martínez-Recio, S, Hernández, A, Morán, T, Arriola, E, Recuero-Borau, J, Cobo, M, Cordeiro, P, Mosquera, J, Fernández, M, García-Campelo, R, Calles, A, Alvarez, R, Zapata-García, M, Isla, D, Callejo, A, Iranzo, P, Serra-López, J, Barba, A, Sullivan, I, Felip, E, Majem, M. First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study. Frontiers in Oncology. 2024; 14DOI:10.3389/fonc.2024.1510278. PMID:39741981. IF:3.300(Q2/4D).
01/11/2024
SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).
Soria Rivas A, Escobar Álvarez Y, Blasco Cordellat A, Majem Tarruella M, Molina Mata K, Motilla de la Cámara M, Del Mar Muñoz Sánchez M, Zafra Poves M, Beato Zambrano C, Cabezón Gutierrez L. SEOM clinical guidelines for cancer anorexia-cachexia syndrome (2023).. Clinical & Translational Oncology. 2024; 26(11)DOI:10.1007/s12094-024-03502-8. PMID:38822976. IF:(Q/D).
01/06/2022
The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles
Volta-Duran, E, Sanchez, JM, Hector-Lopez-Laguna, Parlade, E, Sanchez-Garcia, L, Sanchez-Chardi, A, de Marco, A, Unzueta, U, Vazquez, E, Villaverde, A. The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles. Science China-Materials. 2022; 65(6)DOI:10.1007/s40843-021-1914-0. PMID:. IF:8.100(Q1/3D).
01/05/2022
An In Silico Methodology That Facilitates Decision Making in the Engineering of Nanoscale Protein Materials
Parlade, E, Volta-Duran, E, Cano-Garrido, O, Sanchez, JM, Unzueta, U, Lopez-Laguna, H, Serna, N, Cano, M, Rodriguez-Mariscal, M, Vazquez, E, Villaverde, A. An In Silico Methodology That Facilitates Decision Making in the Engineering of Nanoscale Protein Materials. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(9)DOI:10.3390/ijms23094958. PMID:35563346. IF:5.600(Q1/3D).